Clinuvel Pharmaceuticals Ltd (ASX: CUV), has released its Quarterly Cashflow Report for the period ended 31 December 2019.
- Receipts from customers were $3,734,000, a growth of 43% from the previous corresponding
- Annual receipts increased 19% year-on-year.
- Cash and cash equivalents by the quarter end was $57,435,000, a fall of $901,000 from the previous quarter.
- Expenditure increased as a result of operational expansion.
At AEDT: 1:1:26 PM, CUV shares are trading at $27.900, 3.64% above its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.